Abstract

P 280

Intravitreal bevacizumab (Avastin) for type 2A idiopathic juxtafoveal retinal telangiectasia in a long-term follow-up

Sina Herzog, Rainer Guthoff
Universitäts-Augenklinik Würzburg

Objective
Idiopathic juxtafoveal retinal telangiectasia type 2A (IJT) is an acquired bilateral vascular disease of middle-aged patients involving the capillaries of the temporal fovea. In the natural course of the disease a loss of vision has to be expected. For the last few years, intravitreal bevacizumab has provided a therapeutic option.
Methods
Two patients with bilateral IJT received a single unilateral intravitreal bevacizumab injection (1.5mg) after signing an informed consent form. Visual acuity (VA), fluorescein angiography (FA) and central macular thickness analysis by optical coherence tomography (OCT) were monitored before and after the procedure.
Results
Case 1: A 59-year old female patient was diagnosed with initial VA of 0.4 of the right eye. A juxtafoveal leakage was detected by FA (Stage 3 according to Gass & Blodi). Three months after the intravitreal bevacizumab injection, VA was 0.3 with a decreased leakage. After 7 months, VA stabilized at 0.4 and remained stable for a long-term follow-up term of 27 months. In FA leakage was comparable to the primary findings. VA of the untreated left eye (Stage 3) was stable at 0.6 during the whole period.
Case 2: A 73-year old female patient was diagnosed with VA of 0.2 of the right eye before the bevacizumab injection. FA revealed juxtafoveal leakage of Stage 3 according to Gass & Blodi. Three months and after a long-term follow-up period of 28 months after the injection, VA was unchanged. On FA, temporary reduced leakage was detected at 3 months, but was comparable to the initial findings at last presentation. The VA of the un-treated left eye (Stage 4) was 0.9 and remained stable up to the last visit.
Conclusions
In nonproliferative type 2A IJT, a single intravitreal bevavcizumab treatment leads to a transient decreased leakage on FA, but is not associated with improved VA.

Copyright: 2009 Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.